Freiburg im Breisgau, Germany, April 15, 2025 – Eleva, a pioneer in discovering and developing previously inaccessible biologics based on a breakthrough technology platform, announced today the publication of new data on its lead pipeline asset Factor H (CPV-104) in the peer-reviewed Journal of Neuroinflammation. In an established animal model of age-related macular degeneration (AMD), Eleva’s recombinant human Factor H improved two hallmarks of the disease by statistically significantly dampening the inflammatory activity of microglia and Müller cells in the eye and attenuating light-induced retinal degeneration. To review the full publication, please click here.
“Our innovative Factor H (CPV-104) program continues to generate positive data underlining its broad potential in both complement-related rare disorders and larger indications that correlate with complement deregulation like dry AMD,” commented Andreas Schaaf, Ph.D., Chief Scientific Officer of Eleva. “The in vivo data published today bode well for the ongoing expansion of the development program into additional indications branching out from our initial focus on C3 Glomerulopathy (C3G).”
Dry AMD is a degenerative disease of the retina that can lead to blindness, primarily affecting elderly patients. The complement system plays a central role in dry AMD, driving chronic inflammation and immune cell-mediated killing of retinal cells. The new study, published in collaboration with the University of Cologne, evaluated the effects of intravitreal injections of Factor H (CPV-104) on disease processes such as retinal degradation following light exposure, and indicators of the inflammatory process, such as microglia morphology, localization and migration patterns that drive disease progression. The results provide insights into the neuroprotective and immunomodulatory potential of a human Factor H’s (CPV-104) treatment, indicating that it may be used to delay or prevent dry AMD disease progression in humans.
The full publication, entitled “Moss-derived human complement factor H modulates retinal immune response and attenuates retinal degeneration” is available on the Journal of Neuroinflammation website.
